Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy

Douglas A. Jabs; Janet T. Holbrook; Mark L. Van Natta; Rebecca Clark; Mark A. Jacobson; John H. Kempen; Robert Leo Murphy

doi:10.1016/j.ophtha.2004.10.049

Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy

Douglas A. Jabs^*, Janet T. Holbrook, Mark L. Van Natta, Rebecca Clark, Mark A. Jacobson, John H. Kempen, Robert Leo Murphy

^*Corresponding author for this work

Medicine, Infectious Diseases Division

Research output: Contribution to journal › Article › peer-review

84 Scopus citations

Abstract

Objective: To evaluate risk factors for mortality among patients with AIDS in the era of highly active antiretroviral therapy (HAART), particularly the effect of cytomegalovirus (CMV). Design: Prospective cohort study of patients with AIDS, conducted from 1998 through 2003. Participants: One thousand five hundred eighty-three patients with AIDS, of whom 374 had CMV retinitis. Methods: Patients were contacted every 3 months, with examinations at least every 6 months, in which standardized data were collected on AIDS history and treatment, eye examinations, and hematologic, virologic, and immunologic laboratory data. Main Outcome Measure: Mortality. Results: The overall mortality rate was 0.07 deaths/person-year. In a multivariate analysis, the following baseline risk factors were associated with an increased mortality: higher human immunodeficiency virus (HIV) viral load (relative risk [RR] = 4.6 for HIV viral load >100 000 copies/ml vs. <400 copies/ml; P<0.0001), lower CD4+ T-cell count at enrollment (RR = 3.8 for CD4+ T cell count 0-49 cells/μl vs. ≥200 cells/μl; P<0.0001), CMV viral load ≥400 copies/ml (RR = 1.9; P = 0.002), lower hemoglobin (RR = 1.7 for hemoglobin <10 g/dl; P = 0.009), a history of cryptococcal meningitis (RR = 1.7; P = 0.02), CMV retinitis (RR = 1.6; P = 0.0002), and Karnofsky score ≤80 (RR = 1.4; P = 0.008). Conclusions: In the era of HAART, CMV disease as manifested by CMV retinitis and a detectable CMV viral load were associated with an increased risk for mortality, even after adjusting for demographic, treatment, immunologic, and HIV virologic factors.

Original language	English (US)
Pages (from-to)	771-779
Number of pages	9
Journal	Ophthalmology
Volume	112
Issue number	5
DOIs	https://doi.org/10.1016/j.ophtha.2004.10.049
State	Published - May 1 2005

Funding

Supported by cooperative agreements from the National Eye Institute, National Institutes of Health, Bethesda, Maryland, to The Johns Hopkins University School of Medicine (no.: U10 EY08052), The Johns Hopkins University Bloomberg School of Public Health (no.: U10 EY08057), and the University of Wisconsin, Madison (no.: U10 EY08067). Additional support was provided by the National Center for Research Resources, National Institutes of Health, Bethesda, Maryland, through the General Clinical Research Center (grant nos.: 5MO1 RR00188 [Baylor College of Medicine], MO1 RR00052 [Johns Hopkins University School of Medicine], 5MO1 RR05096 [Louisiana State University], 5MO1 RR00865 [University of California, Los Angeles], 5MO1 RR05280 [University of Miami], 5M01 RR00046 [University of North Carolina], 5MO1 RR00043 [University of Southern California], 5MO1 RR00047 [Weill Medical College of Cornell University]). Dr Jabs is the recipient of a Research to Prevent Blindness (New York, New York) Senior Scientific Investigator Award.

ASJC Scopus subject areas

Ophthalmology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ophtha.2004.10.049

Cite this

@article{81cc571a34484b328fefa90b2f99398d,

title = "Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy",

abstract = "Objective: To evaluate risk factors for mortality among patients with AIDS in the era of highly active antiretroviral therapy (HAART), particularly the effect of cytomegalovirus (CMV). Design: Prospective cohort study of patients with AIDS, conducted from 1998 through 2003. Participants: One thousand five hundred eighty-three patients with AIDS, of whom 374 had CMV retinitis. Methods: Patients were contacted every 3 months, with examinations at least every 6 months, in which standardized data were collected on AIDS history and treatment, eye examinations, and hematologic, virologic, and immunologic laboratory data. Main Outcome Measure: Mortality. Results: The overall mortality rate was 0.07 deaths/person-year. In a multivariate analysis, the following baseline risk factors were associated with an increased mortality: higher human immunodeficiency virus (HIV) viral load (relative risk [RR] = 4.6 for HIV viral load >100 000 copies/ml vs. <400 copies/ml; P<0.0001), lower CD4+ T-cell count at enrollment (RR = 3.8 for CD4+ T cell count 0-49 cells/μl vs. ≥200 cells/μl; P<0.0001), CMV viral load ≥400 copies/ml (RR = 1.9; P = 0.002), lower hemoglobin (RR = 1.7 for hemoglobin <10 g/dl; P = 0.009), a history of cryptococcal meningitis (RR = 1.7; P = 0.02), CMV retinitis (RR = 1.6; P = 0.0002), and Karnofsky score ≤80 (RR = 1.4; P = 0.008). Conclusions: In the era of HAART, CMV disease as manifested by CMV retinitis and a detectable CMV viral load were associated with an increased risk for mortality, even after adjusting for demographic, treatment, immunologic, and HIV virologic factors.",

author = "Jabs, {Douglas A.} and Holbrook, {Janet T.} and {Van Natta}, {Mark L.} and Rebecca Clark and Jacobson, {Mark A.} and Kempen, {John H.} and Murphy, {Robert Leo}",

note = "Funding Information: Supported by cooperative agreements from the National Eye Institute, National Institutes of Health, Bethesda, Maryland, to The Johns Hopkins University School of Medicine (no.: U10 EY08052), The Johns Hopkins University Bloomberg School of Public Health (no.: U10 EY08057), and the University of Wisconsin, Madison (no.: U10 EY08067). Additional support was provided by the National Center for Research Resources, National Institutes of Health, Bethesda, Maryland, through the General Clinical Research Center (grant nos.: 5MO1 RR00188 [Baylor College of Medicine], MO1 RR00052 [Johns Hopkins University School of Medicine], 5MO1 RR05096 [Louisiana State University], 5MO1 RR00865 [University of California, Los Angeles], 5MO1 RR05280 [University of Miami], 5M01 RR00046 [University of North Carolina], 5MO1 RR00043 [University of Southern California], 5MO1 RR00047 [Weill Medical College of Cornell University]). Dr Jabs is the recipient of a Research to Prevent Blindness (New York, New York) Senior Scientific Investigator Award. Copyright: Copyright 2008 Elsevier B.V., All rights reserved.",

year = "2005",

month = may,

day = "1",

doi = "10.1016/j.ophtha.2004.10.049",

language = "English (US)",

volume = "112",

pages = "771--779",

journal = "Ophthalmology",

issn = "0161-6420",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy

AU - Jabs, Douglas A.

AU - Holbrook, Janet T.

AU - Van Natta, Mark L.

AU - Clark, Rebecca

AU - Jacobson, Mark A.

AU - Kempen, John H.

AU - Murphy, Robert Leo

N1 - Funding Information: Supported by cooperative agreements from the National Eye Institute, National Institutes of Health, Bethesda, Maryland, to The Johns Hopkins University School of Medicine (no.: U10 EY08052), The Johns Hopkins University Bloomberg School of Public Health (no.: U10 EY08057), and the University of Wisconsin, Madison (no.: U10 EY08067). Additional support was provided by the National Center for Research Resources, National Institutes of Health, Bethesda, Maryland, through the General Clinical Research Center (grant nos.: 5MO1 RR00188 [Baylor College of Medicine], MO1 RR00052 [Johns Hopkins University School of Medicine], 5MO1 RR05096 [Louisiana State University], 5MO1 RR00865 [University of California, Los Angeles], 5MO1 RR05280 [University of Miami], 5M01 RR00046 [University of North Carolina], 5MO1 RR00043 [University of Southern California], 5MO1 RR00047 [Weill Medical College of Cornell University]). Dr Jabs is the recipient of a Research to Prevent Blindness (New York, New York) Senior Scientific Investigator Award. Copyright: Copyright 2008 Elsevier B.V., All rights reserved.

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Objective: To evaluate risk factors for mortality among patients with AIDS in the era of highly active antiretroviral therapy (HAART), particularly the effect of cytomegalovirus (CMV). Design: Prospective cohort study of patients with AIDS, conducted from 1998 through 2003. Participants: One thousand five hundred eighty-three patients with AIDS, of whom 374 had CMV retinitis. Methods: Patients were contacted every 3 months, with examinations at least every 6 months, in which standardized data were collected on AIDS history and treatment, eye examinations, and hematologic, virologic, and immunologic laboratory data. Main Outcome Measure: Mortality. Results: The overall mortality rate was 0.07 deaths/person-year. In a multivariate analysis, the following baseline risk factors were associated with an increased mortality: higher human immunodeficiency virus (HIV) viral load (relative risk [RR] = 4.6 for HIV viral load >100 000 copies/ml vs. <400 copies/ml; P<0.0001), lower CD4+ T-cell count at enrollment (RR = 3.8 for CD4+ T cell count 0-49 cells/μl vs. ≥200 cells/μl; P<0.0001), CMV viral load ≥400 copies/ml (RR = 1.9; P = 0.002), lower hemoglobin (RR = 1.7 for hemoglobin <10 g/dl; P = 0.009), a history of cryptococcal meningitis (RR = 1.7; P = 0.02), CMV retinitis (RR = 1.6; P = 0.0002), and Karnofsky score ≤80 (RR = 1.4; P = 0.008). Conclusions: In the era of HAART, CMV disease as manifested by CMV retinitis and a detectable CMV viral load were associated with an increased risk for mortality, even after adjusting for demographic, treatment, immunologic, and HIV virologic factors.

AB - Objective: To evaluate risk factors for mortality among patients with AIDS in the era of highly active antiretroviral therapy (HAART), particularly the effect of cytomegalovirus (CMV). Design: Prospective cohort study of patients with AIDS, conducted from 1998 through 2003. Participants: One thousand five hundred eighty-three patients with AIDS, of whom 374 had CMV retinitis. Methods: Patients were contacted every 3 months, with examinations at least every 6 months, in which standardized data were collected on AIDS history and treatment, eye examinations, and hematologic, virologic, and immunologic laboratory data. Main Outcome Measure: Mortality. Results: The overall mortality rate was 0.07 deaths/person-year. In a multivariate analysis, the following baseline risk factors were associated with an increased mortality: higher human immunodeficiency virus (HIV) viral load (relative risk [RR] = 4.6 for HIV viral load >100 000 copies/ml vs. <400 copies/ml; P<0.0001), lower CD4+ T-cell count at enrollment (RR = 3.8 for CD4+ T cell count 0-49 cells/μl vs. ≥200 cells/μl; P<0.0001), CMV viral load ≥400 copies/ml (RR = 1.9; P = 0.002), lower hemoglobin (RR = 1.7 for hemoglobin <10 g/dl; P = 0.009), a history of cryptococcal meningitis (RR = 1.7; P = 0.02), CMV retinitis (RR = 1.6; P = 0.0002), and Karnofsky score ≤80 (RR = 1.4; P = 0.008). Conclusions: In the era of HAART, CMV disease as manifested by CMV retinitis and a detectable CMV viral load were associated with an increased risk for mortality, even after adjusting for demographic, treatment, immunologic, and HIV virologic factors.

UR - http://www.scopus.com/inward/record.url?scp=18244378223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18244378223&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2004.10.049

DO - 10.1016/j.ophtha.2004.10.049

M3 - Article

C2 - 15878056

AN - SCOPUS:18244378223

SN - 0161-6420

VL - 112

SP - 771

EP - 779

JO - Ophthalmology

JF - Ophthalmology

IS - 5

ER -

Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this